Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
Nurix Therapeutics, Inc. (NASDAQ: NRIX) will present at the 3rd Targeted Protein Degradation Summit on October 14, 2020, at 1:50 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nurix Therapeutics, Inc. (NASDAQ: NRIX) will present at the 3rd Targeted Protein Degradation Summit on October 14, 2020, at 1:50 p.m. EDT. The session, titled Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels, will be led by CEO Arthur Sands, M.D., Ph.D. Nurix focuses on developing small molecule therapies to modulate cellular protein levels, aiming to treat cancer and immune disorders. Their integrated discovery platform, DELigase, identifies and advances drug candidates targeting E3 ligases.
Details
News Market Reaction – NRIX
The recorded move for NRIX in the trading session of this news was -1.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.
Additional details on the presentation are below:
3rd Targeted Protein Degradation (TPD) Summit
Session: Robust Translation Towards Clinical Development
Title: Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels
Presenter: Arthur Sands, M.D., Ph.D., CEO
Date: Wednesday, October 14, 2020
Time: 1:50 p.m. EDT
Copies of the slide presentation will be archived and available in the Investors section of the Company’s website at www.nurix.com.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.
Contacts:
Investors:
Jason Kantor
Nurix Therapeutics, Inc.
jkantor@nurixtx.com
Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.